424 related articles for article (PubMed ID: 8972476)
1. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
2. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
4. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
5. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.
Santin AD; Diamandis EP; Bellone S; Marizzoni M; Bandiera E; Palmieri M; Papasakelariou C; Katsaros D; Burnett A; Pecorelli S
Am J Obstet Gynecol; 2006 May; 194(5):1296-302. PubMed ID: 16647913
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
[TBL] [Abstract][Full Text] [Related]
9. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
10. Hysteroscopic and immunohistochemical findings in type I and type II endometrial carcinomas.
Maia H; Maltez A; Fahel P; Coutinho E
J Am Assoc Gynecol Laparosc; 2001 May; 8(2):222-30. PubMed ID: 11342729
[TBL] [Abstract][Full Text] [Related]
11. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
Soslow RA; Shen PU; Chung MH; Isacson C
Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
[TBL] [Abstract][Full Text] [Related]
12. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
[TBL] [Abstract][Full Text] [Related]
13. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
[TBL] [Abstract][Full Text] [Related]
14. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
[TBL] [Abstract][Full Text] [Related]
15. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH
Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673
[TBL] [Abstract][Full Text] [Related]
16. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
17. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
[TBL] [Abstract][Full Text] [Related]
18. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
19. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
20. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]